Amarin – an overnight success 10 years in the making
After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market
Amarin raises doubts over future prospects
Drug firms questions whether it can afford to fund trial central to growth plans
Losses at Amarin widen despite strong revenues from new drug
Irish biopharma group regonised revenues of $5.5m from its new Vascepa drug in Q2
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices